Cargando…
Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma
We present feasibility, toxicity and efficacy results of an intensified six-cycle ChlVPP/ABVVP regimen in advanced Hodgkin lymphoma (HL). From February 2004 to August 2007, 82 consecutive eligible patients were enrolled. According to the Hasenclever index, 64 patients (78%) were considered at low ri...
Autores principales: | Cocorocchio, E, Vanazzi, A, Bassi, S, Peccatori, F, Antoniotti, P, Gigli, F, Travaini, L, Piperno, G, Pruneri, G, Preda, L, Biffi, R, Botteri, E, Negri, M, Martinelli, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234024/ https://www.ncbi.nlm.nih.gov/pubmed/22276036 http://dx.doi.org/10.3332/ecancer.2010.184 |
Ejemplares similares
-
ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.
por: Selby, P., et al.
Publicado: (1990) -
Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
por: Dady, P. J., et al.
Publicado: (1982) -
ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial
por: Hancock, B W, et al.
Publicado: (2001) -
Lattice QCD calculation using VPP500
por: Kim, S, et al.
Publicado: (1994) -
AntiVPP 1.0: A portable tool for prediction of antiviral peptides
por: Beltrán Lissabet, Jorge Félix, et al.
Publicado: (2019)